The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
The emergence and epidemic characteristics of the highly mutated SARS‐CoV‐2 Omicron variant
Open accessAbstract
Recently, the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) Omicron variant (B.1.1.529) was first identified in Botswana in November 2021. It was first reported to the World Health Organization (WHO) on November 24. On November 26, 2021, according to the advice of scientists who are part of the WHO's Technical Advisory Group on SARS‐CoV‐2 Virus Evolution (TAG‐VE), the WHO defined the strain as a variant of concern (VOC) and named it Omicron. Compared to the other four VOCs (Alpha, Beta, Gamma, and Delta), the Omicron variant was the most highly mutated strain, with 50 mutations accumulated throughout the genome. The Omicron variant contains at least 32 mutations in the spike protein, which was twice as many as the Delta variant. Studies have shown that carrying many mutations can increase infectivity and immune escape of the Omicron variant compared with the early wild‐type strain and the other four VOCs. The Omicron variant is becoming the dominant strain in many countries worldwide and brings new challenges to preventing and controlling coronavirus disease 2019 (COVID‐19). The current review article aims to analyze and summarize information data about the biological characteristics of amino acid mutations, the epidemic characteristics, immune escape, and vaccine reactivity of the Omicron variant, hoping to provide a scientific reference for monitoring, prevention, and vaccine development strategies for the Omicron variant.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30251-8 · Cited by 11,907
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2180-5 · Cited by 5,983
SARS-CoV-2 variants, spike mutations and immune escape
Harvey, W. T., Carabelli, A. M., Jackson, B., Gupta, R. K., Thomson, E. C., Harrison, E. M., Ludden, C., Reeve, R., Rambaut, A., COVID-19 Genomics UK (COG-UK) Consortium, et al. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00573-0 · Cited by 3,528 · cited 2×
“Adaptive mutation of the SARS‐CoV‐2 genome can change the infectivity, immune evasion, and phenotypic characteristics of the virus.(13,14,20) The emergence of the Omicron”
BackgroundEpidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses
Su, S., Wong, G., Shi, W., Liu, J., Lai, A. C. K., Zhou, J., Liu, W., Bi, Y., & Gao, G. F. (2016) · Trends in Microbiology · doi:10.1016/j.tim.2016.03.003 · Cited by 2,948
The pathogenesis and treatment of the `Cytokine Storm' in COVID-19
Ye, Q., Wang, B., & Mao, J. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.03.037 · Cited by 2,761
Self-citationEffectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern
Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Rickeard, T., Gallagher, E., Gower, C., Kall, M., Groves, N., O’Connell, A.-M., et al. (2021) · doi:10.1101/2021.12.14.21267615 · Cited by 2,420 · cited 1×
“5%, respectively) after 2 weeks.(67) Similarly, one study from Doria‐Rose NA's team showed that Omicron was 41–84‐fold and 5.”
Starr, T. N., Greaney, A. J., Hilton, S. K., Ellis, D., Crawford, K. H. D., Dingens, A. S., Navarro, M. J., Bowen, J. E., Tortorici, M. A., Walls, A. C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.012 · Cited by 1,956
Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil
Faria, N. R., Mellan, T. A., Whittaker, C., Claro, I. M., Candido, D. D. S., Mishra, S., Crispim, M. A. E., Sales, F. C. S., Hawryluk, I., McCrone, J. T., et al. (2021) · Science · doi:10.1126/science.abh2644 · Cited by 1,461
A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
Chi, X., Yan, R., Zhang, J., Zhang, G., Zhang, Y., Hao, M., Zhang, Z., Fan, P., Dong, Y., Yang, Y., et al. (2020) · Science · doi:10.1126/science.abc6952 · Cited by 1,385
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
Wang, Z., Schmidt, F., Weisblum, Y., Muecksch, F., Barnes, C. O., Finkin, S., Schaefer-Babajew, D., Cipolla, M., Gaebler, C., Lieberman, J. A., et al. (2021) · Nature · doi:10.1038/s41586-021-03324-6 · Cited by 1,343
SARS-CoV-2 evolution during treatment of chronic infection
Kemp, S. A., Collier, D. A., Datir, R. P., Ferreira, I. A. T. M., Gayed, S., Jahun, A., Hosmillo, M., Rees-Spear, C., Mlcochova, P., Lumb, I. U., et al. (2021) · Nature · doi:10.1038/s41586-021-03291-y · Cited by 1,097
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Cameroni, E., Bowen, J. E., Rosen, L. E., Saliba, C., Zepeda, S. K., Culap, K., Pinto, D., VanBlargan, L. A., De Marco, A., di Iulio, J., et al. (2022) · Nature · doi:10.1038/s41586-021-04386-2 · Cited by 1,080
Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa
Pulliam, J. R. C., van Schalkwyk, C., Govender, N., Gottberg, A. V., Cohen, C., Groome, M. J., Dushoff, J., Mlisana, K., & Moultrie, H. (2021) · doi:10.1101/2021.11.11.21266068 · Cited by 1,037
Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity
Volz, E., Hill, V., McCrone, J. T., Price, A., Jorgensen, D., O’Toole, Á., Southgate, J., Johnson, R., Jackson, B., Nascimento, F. F., et al. (2021) · Cell · doi:10.1016/j.cell.2020.11.020 · Cited by 1,006
Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant
Pachetti, M., Marini, B., Benedetti, F., Giudici, F., Mauro, E., Storici, P., Masciovecchio, C., Angeletti, S., Ciccozzi, M., Gallo, R. C., et al. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02344-6 · Cited by 996
SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo
Hou, Y. J., Chiba, S., Halfmann, P., Ehre, C., Kuroda, M., Dinnon, K. H., Leist, S. R., Schäfer, A., Nakajima, N., Takahashi, K., et al. (2020) · Science · doi:10.1126/science.abe8499 · Cited by 900
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies
Planas, D., Bruel, T., Grzelak, L., Guivel-Benhassine, F., Staropoli, I., Porrot, F., Planchais, C., Buchrieser, J., Rajah, M. M., Bishop, E., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01318-5 · Cited by 697
Leung, K., Shum, M. H., Leung, G. M., Lam, T. T., & Wu, J. T. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.26.1.2002106 · Cited by 694 · cited 1×
“Compared with the early original strains, many clinical studies have suggested that Alpha, Beta, and Delta variants increase the risk of hospitalization, ICU admission, and death.(8,9,11,12) Previously reported cases from South Africa(46) and 43 cases of Omicron in the United States(53,54) found that the symptoms of c…”
BackgroundOmicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance
Chen, J., Wang, R., Gilby, N. B., & Wei, G.-W. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c01451 · Cited by 653
SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution
Zahradník, J., Marciano, S., Shemesh, M., Zoler, E., Harari, D., Chiaravalli, J., Meyer, B., Rudich, Y., Li, C., Marton, I., et al. (2021) · Nature Microbiology · doi:10.1038/s41564-021-00954-4 · Cited by 457
SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
Pajon, R., Doria-Rose, N. A., Shen, X., Schmidt, S. D., O’Dell, S., McDanal, C., Feng, W., Tong, J., Eaton, A., Maglinao, M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2119912 · Cited by 457
Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and Monoclonal Antibodies
Wilhelm, A., Widera, M., Grikscheit, K., Toptan, T., Schenk, B., Pallas, C., Metzler, M., Kohmer, N., Hoehl, S., Helfritz, F. A., et al. (2021) · doi:10.1101/2021.12.07.21267432 · Cited by 440
Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7
Meng, B., Kemp, S. A., Papa, G., Datir, R., Ferreira, I. A. T. M., Marelli, S., Harvey, W. T., Lytras, S., Mohamed, A., Gallo, G., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109292 · Cited by 405
The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron
Zhang, L., Li, Q., Liang, Z., Li, T., Liu, S., Cui, Q., Nie, J., Wu, Q., Qu, X., Huang, W., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.2017757 · Cited by 357
SARS-CoV-2 variants of concern are emerging in India
Singh, J., Rahman, S. A., Ehtesham, N. Z., Hira, S., & Hasnain, S. E. (2021) · Nature Medicine · doi:10.1038/s41591-021-01397-4 · Cited by 355
SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape
Li, Q., Nie, J., Wu, J., Zhang, L., Ding, R., Wang, H., Zhang, Y., Li, T., Liu, S., Zhang, M., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.042 · Cited by 354
Torjesen, I. (2021) · BMJ · doi:10.1136/bmj.n2943 · Cited by 348
Ai, J., Zhang, H., Zhang, Y., Lin, K., Zhang, Y., Wu, J., Wan, Y., Huang, Y., Song, J., Fu, Z., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.2022440 · Cited by 339
Delta coronavirus variant: scientists brace for impact
Callaway, E. (2021) · Nature · doi:10.1038/d41586-021-01696-3 · Cited by 291
Benvenuto, D., Angeletti, S., Giovanetti, M., Bianchi, M., Pascarella, S., Cauda, R., Ciccozzi, M., & Cassone, A. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.03.058 · Cited by 255
Wang, R., Zhang, Q., Ge, J., Ren, W., Zhang, R., Lan, J., Ju, B., Su, B., Yu, F., Chen, P., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.06.003 · Cited by 240
High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape
Schmidt, F., Weisblum, Y., Rutkowska, M., Poston, D., DaSilva, J., Zhang, F., Bednarski, E., Cho, A., Schaefer-Babajew, D. J., Gaebler, C., et al. (2021) · Nature · doi:10.1038/s41586-021-04005-0 · Cited by 215
Omicron variant (B.1.1.529) of SARS‐CoV‐2, a global urgent public health alert!
Gao, S., Guo, H., & Luo, G. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27491 · Cited by 205
The Global Epidemic of the SARS-CoV-2 Delta Variant, Key Spike Mutations and Immune Escape
Tian, D., Sun, Y., Zhou, J., & Ye, Q. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.751778 · Cited by 198
Self-citationGu, H., Krishnan, P., Ng, D. Y. M., Chang, L. D. J., Liu, G. Y. Z., Cheng, S. S. M., Hui, M. M. Y., Fan, M. C. Y., Wan, J. H. L., Lau, L. H. K., et al. (2022) · Emerging Infectious Diseases · doi:10.3201/eid2802.212422 · Cited by 175
The mechanism and treatment of gastrointestinal symptoms in patients with COVID-19
Ye, Q., Wang, B., Zhang, T., Xu, J., & Shang, S. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00148.2020 · Cited by 158
Self-citationThe basis of a more contagious 501Y.V1 variant of SARS-CoV-2
Liu, H., Zhang, Q., Wei, P., Chen, Z., Aviszus, K., Yang, J. J., Downing, W., Peterson, S., Liang, B., Liang, B., et al. (2021) · Cell Research · doi:10.1038/s41422-021-00496-8 · Cited by 156
Epidemiological analysis of COVID‐19 and practical experience from China
Ye, Q., Wang, B., Mao, J., Fu, J., Shang, S., Shu, Q., & Zhang, T. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25813 · Cited by 149
Self-citationMaitra, A., Chawla‐Sarkar, M., Raheja, H., Biswas, N. K., Chakraborti, S., Singh, A. K., Ghosh, S., Sarkar, S., Patra, S., Mondal, R., et al. (2020) · Journal of Biosciences · doi:10.1007/s12038-020-00046-1 · Cited by 133
Hepatic complications of COVID‐19 and its treatment
Tian, D., & Ye, Q. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26036 · Cited by 131
Self-citationAnalysis of COVID‐19 vaccines: Types, thoughts, and application
Han, X., Xu, P., & Ye, Q. (2021) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23937 · Cited by 123
Self-citationThe global epidemic of SARS‐CoV‐2 variants and their mutational immune escape
Tian, D., Sun, Y., Zhou, J., & Ye, Q. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27376 · Cited by 108
Self-citationKidney involvement in COVID‐19 and its treatments
Han, X., & Ye, Q. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26653 · Cited by 103
Self-citationSignatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies
Alenquer, M., Ferreira, F., Lousa, D., Valério, M., Medina-Lopes, M., Bergman, M., Gonçalves, J., Demengeot, J., Leite, R. B., Lilue, J., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009772 · Cited by 102
Characteristics of coagulation alteration in patients with COVID-19
Luo, H.-C., You, C.-Y., Lu, S.-W., & Fu, Y. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04305-x · Cited by 86
Cellular Immune Response to COVID-19 and Potential Immune Modulators
Zhou, X. K., & Ye, Q. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.646333 · Cited by 79
Self-citationCovid-19: South Africa’s surge in cases deepens alarm over omicron variant
Dyer, O. (2021) · BMJ · doi:10.1136/bmj.n3013 · Cited by 78
Omicron (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistancePreprint
Chen, J., Wang, R., Gilby, N. B., & Wei, G. (2021) · PubMed · doi:10.48550/arxiv.2112.01318 · Cited by 78
The variants of SARS‐CoV‐2 and the challenges of vaccines
Han, X., & Ye, Q. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27513 · Cited by 37
Self-citationAssessment of global asymptomatic SARS-CoV-2 infection and management practices from China
Zheng, C., Wang, B., Mao, S., & Ye, Q. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59374 · Cited by 36
Self-citationŞahin, E., Bozdayı, G., Yiğit, S., Muftah, H., Dizbay, M., Tunçcan, Ö. G., Fidan, I., & Çağlar, K. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27188 · Cited by 31
Mertens, J. C., Coppens, J., Loens, K., Mercier, M. L., Xavier, B. B., Lammens, C., Vandamme, S., Jansens, H., Goossens, H., & Matheeussen, V. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.09.007 · Cited by 28
Crosstalk Between Coronavirus Disease 2019 and Cardiovascular Disease and Its Treatment
Ye, Q., Lu, D., Shang, S., Fu, J., Gong, F., Shu, Q., & Mao, J. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12960 · Cited by 24
Self-citationSARS‐CoV‐2 effects on the renin‐angiotensin‐aldosterone system, therapeutic implications
Ye, Q., Lai, E. Y., Luft, F. C., Persson, P. B., & Mao, J. (2020) · Acta Physiologica · doi:10.1111/apha.13608 · Cited by 18
Self-citationAnalysis of SARS-COV2 spike protein variants among Iraqi isolates
Sabir, D. K. (2021) · Gene Reports · doi:10.1016/j.genrep.2021.101420 · Cited by 15
Cited by
SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies
Cox, M., Peacock, T. P., Harvey, W. T., Hughes, J., Wright, D. W., COVID-19 Genomics UK (COG-UK) Consortium, Willett, B. J., Thomson, E., Gupta, R. K., Peacock, S. J., et al. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00809-7 · Cited by 344
Kumar, S., Karuppanan, K., & Subramaniam, G. (2022) · doi:10.1101/2022.02.11.480029 · Cited by 223
Song, S., Madewell, Z. J., Liu, M., Longini, I. M., & Yang, Y. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1195908 · Cited by 34
Post-Vaccination Neutralization Responses to Omicron Sub-Variants
Jacobsen, H., Katzmarzyk, M., Higdon, M. M., Jiménez, V. C., Sitaras, I., Bar-Zeev, N., & Knoll, M. D. (2022) · Vaccines · doi:10.3390/vaccines10101757 · Cited by 21
Metadata
- Authors
- Tian, D., Sun, Y., Xu, H., & Ye, Q.
- Venue
- Journal of Medical Virology
- Publisher
- Wiley
- Published
- 2022-02-11
- Volume
- 94
- Issue
- 6
- Pages
- 2376-2383
- ISSN
- 0146-6615 (ISSN-L)
- 1096-9071
- OpenAlex
- W4210365826
- Cited by
- 468
- References
- 57
- FWCI
- 51.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.